Mergers and acquisitions are not just for Big Pharma. A new report from Leerink Partners takes a stab at identifying the ...
BioMarin no longer expects to hit its $4 billion revenue target by 2027, citing various market factors such as impending ...
Phase I/II data for rese-cel point to its therapeutic potential in systemic lupus erythematosus and lupus nephritis, as well ...
Vas Narasimhan confirmed that Novartis is having weekly discussions with the Trump administration on drug pricing, but a deal ...
The coming flu season is the clearest indication yet that biopharma’s long-standing assumptions about predictability, ...
Phase III data for dapirolizumab pegol presented at the 2025 American College of Rheumatology showed quality-of-life benefits ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback